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Abstract
Background: The recent emergence of a novel pandemic influenza A(H1N1) strain in humans exemplifies the rapid and
unpredictable nature of influenza virus evolution and the need for effective therapeutics and vaccines to control such
outbreaks. However, resistance to antivirals can be a formidable problem as evidenced by the currently widespread
oseltamivir- and adamantane-resistant seasonal influenza A viruses (IFV). Additional antiviral approaches with novel
mechanisms of action are needed to combat novel and resistant influenza strains. DAS181 (Fludase
TM) is a sialidase fusion
protein in early clinical development with in vitro and in vivo preclinical activity against a variety of seasonal influenza strains
and highly pathogenic avian influenza strains (A/H5N1). Here, we use in vitro, ex vivo, and in vivo models to evaluate the
activity of DAS181 against several pandemic influenza A(H1N1) viruses.
Methods and Findings: The activity of DAS181 against several pandemic influenza A(H1N1) virus isolates was examined in
MDCK cells, differentiated primary human respiratory tract culture, ex-vivo human bronchi tissue and mice. DAS181
efficiently inhibited viral replication in each of these models and against all tested pandemic influenza A(H1N1) strains.
DAS181 treatment also protected mice from pandemic influenza A(H1N1)-induced pathogenesis. Furthermore, DAS181
antiviral activity against pandemic influenza A(H1N1) strains was comparable to that observed against seasonal influenza
virus including the H274Y oseltamivir-resistant influenza virus.
Conclusions: The sialidase fusion protein DAS181 exhibits potent inhibitory activity against pandemic influenza A(H1N1)
viruses. As inhibition was also observed with oseltamivir-resistant IFV (H274Y), DAS181 may be active against the
antigenically novel pandemic influenza A(H1N1) virus should it acquire the H274Y mutation. Based on these and previous
results demonstrating DAS181 broad-spectrum anti-IFV activity, DAS181 represents a potential therapeutic agent for
prevention and treatment of infections by both emerging and seasonal strains of IFV.
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Introduction
In the United States alone influenza virus (IFV) causes over
200,000 hospitalizations annually and is responsible for approx-
imately 36,000 deaths every year [1,2]. The emergence of
antigenically novel strains or drug-resistant IFV strains is of major
public health concern in light of the burden of seasonal influenza
and the persistent threat of pandemic influenza. Indeed, the recent
outbreak of pandemic influenza A(H1N1) (novel 2009 A(H1N1),
‘‘swine influenza’’) is a reminder that non-human IFV are capable
of evolving to infect humans, and as such remain a continuous
public health threat [3–6]. Antigenically novel strains such as
pandemic IFV A(H1N1) present a particular problem as the
human population is largely serologically naı ¨ve to the novel virus,
and vaccination with seasonal influenza vaccine does not elicit
protective levels of cross-reactive antibody to the novel virus [7]. In
addition, antiviral resistance among certain influenza strains is a
growing problem [8–11]. Nowhere is this more evident than in the
dramatic rise of oseltamivir-resistant seasonal H1N1 influenza and
adamantane-resistant seasonal H3N2 viruses in the past few years
[8,10,12–14]. Predicting the future evolution of influenza viruses
and their sensitivity to available antivirals and vaccines remains an
PLoS ONE | www.plosone.org 1 November 2009 | Volume 4 | Issue 11 | e7788ongoing public health concern. Additional effective anti-influenza
therapeutics are clearly needed [15].
The pandemic influenza A(H1N1) outbreak is believed to have
originated in central Mexico in the spring of 2009 and rapidly
spread across the globe. This strain of IFV contains gene segments
from common avian, swine and human influenza strains [16].
While birds are a well known reservoir of a great variety of
antigenically distinct influenza subtypes (e.g., highly virulent
H5N1), swine are considered the ‘‘mixing vessel’’ for generating
novel strains of IFV that can also infect humans [6]. This ‘‘mixing
vessel’’ effect is due to the fact besides the classic swine viruses, pigs
are susceptible to infection by both avian and human influenza
viruses. Co-infection with viruses of various origins allows for
reassortment of gene segments and a genesis of viruses with a new
gene constellation such as seen in triple reassortment swine viruses
[6]. Even with this apparent mechanism for rapid evolution in
place most influenza viruses of avian or swine origin have
exhibited difficulty in transmission between humans [6,17,18]. In
contrast one of the alarming hallmarks of the pandemic influenza
A(H1N1) virus is that it appears readily transmissible between
humans.
Because new IFV strains often are so antigenically different
from seasonal human IFV, current vaccines and preexisting serum
antibodies are unlikely to offer effective protection; indeed this is
the case with the novel 2009 pandemic influenza A(H1N1) [7].
This fact, and the time lag involved in producing a pandemic
influenza A(H1N1) vaccine, suggests that acute approaches such as
antiviral drugs are needed to complement the available infection
control measures.
DAS181 (Fludase
TM) is a recombinant fusion protein composed
of the catalytic domain of Actinomyces viscosus sialidase and the
epithelial anchoring domain of human amphiregulin (AR). This
45 kDa protein has been shown to bind to cells and efficiently
remove cell-surface sialic acid residues from respiratory epithelium
[19,20]. Sialic acid is the primary receptor for IFV binding and
entry into the host cell, therefore removal of sialic acid by DAS181
potently inhibits IFV infection [19,21]. Furthermore, by targeting
the host cells rather than the virus, DAS181 may be less likely to
induce drug resistance than virus-targeting compounds (e.g.
adamantanes and neuraminidase inhibitors). DAS181 has dem-
onstrated inhibition of infection by over 30 IFV strains in MDCK
cells, human airway epithelium cultures (wdHAE), ex vivo human
lung and bronchi tissues, mice, and ferrets [19,20,22–24].
Furthermore, DAS181 also protected mice from lethal challenge
with highly pathogenic avian influenza virus (HPAI) (H5N1) with
treatment as late as 72 hours post-infection [22].
Because of the broad-spectrum activity of DAS181 against
both laboratory and clinically isolated IFV strains, we hypoth-
esized that it might also be effective against the novel pandemic
influenza A(H1N1) virus. Here we show potent in vitro, ex vivo,
and in vivo inhibition of several 2009 pandemic influenza
A(H1N1) clinical isolates and an oseltamivir-resistant clinical
isolate, by DAS181.
Results
DAS181 Inhibits Pandemic Influenza A(H1N1) Clinical
Isolates In Vitro
To determine if DAS181 is active against the pandemic
influenza A (H1N1) (2009 A(H1N1)) two viruses obtained from
Mexico and California in April of 2009 were tested for sensitivity
to DAS181. MDCK cells pretreated with DAS181 (2 hrs) were
inoculated with these viruses and subsequent viral replication was
compared to that in untreated MDCK cells at 24 hrs post-
infection. To this end, cell culture supernatants were harvested to
determine the infectious virus yields (infectious progeny produc-
tion/release) while the MDCK cell monolayers were inspected for
the presence of infected cells forming foci (clusters of infected cells)
using immunofluorescent detection of the viral NP antigen.
Numerous and large sized foci were detected in untreated MDCK
cell culture whereas in DAS181 pre-treated monolayers, the foci
were very small in size and a qualitative dose-dependent reduction
in foci number was also observed. DAS181 concentrations as low
as 0.04 mM substantially reduced the amount of virus-positive foci
using the A/California/4/2009 or A/Mexico/4604/2009 H1N1
viruses (Figure 1). Quantifying the number of infected foci
indicated DAS181 EC50 values to be ,0.04 mM (Table 1).
Quantifying the amount of virus progeny in the cell supernatants
also revealed consistent results and a dose-dependent reduction of
pandemic IFV A(H1N1) replication by DAS181 (Table 2). In
comparison, DAS181 was similarly effective against two seasonal
influenza A/H1N1 strains (one oseltamivir-sensitive and one
oseltamivir-resistant) in the same assay (Table 1, Table 2). This
result shows that DAS181 is highly active against the pandemic
Figure 1. DAS181 inhibits pandemic IFV A(H1N1): Immunofluorescent detection of 2009 A(H1N1) foci in MDCK cells. MDCK cells were
pretreated with DAS181 for 2 hours (at indicated concentrations) before infection with either pandemic influenza A(H1N1) A/Mexico/4604/09
(Mexico) or A/California/04/09 (California). After 24 hrs post-infection, the cultures were fixed and processed for immunostaining to detect virus
antigen as marker of infected cells. White spots indicate infected cells that form foci (clusters) of different size ranging from 5 to 100’s of individual
infected cells.
doi:10.1371/journal.pone.0007788.g001
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comparable to that against seasonal IFV A.
The A/Mexico/4604/2009 and A/California/04/2009
A(H1N1) isolates were also tested for DAS181 sensitivity in a
well differentiated primary human airway epithelium culture
model (HAE). The HAE model better represents the human
airway (compared to cell line models) in that it contains all the
functional cell types found in the airway (ciliated, secretory,
and basal cells) and more accurately represents the expression
pattern of sialic acids found in the upper human respiratory
tract [25–30]. The HAE model supported robust infection by
both 2009 A(H1N1) viruses and DAS181 strongly inhibited
replication of both strains at several multiplicities of infection
(Figure 2).
DAS181 Inhibits Pandemic Influenza A(H1N1) Virus in Ex
Vivo Human Bronchi Tissue
Because MDCK cells do not accurately represent the human
respiratory tract in terms of cell type and fine sialic acid structure
milieu, and HAE cultures are extensively cultured in vitro, the
activity of DAS181 against pandemic IFV A(H1N1) was tested
using fresh human bronchi tissue. Tissues were obtained from
patients undergoing lung resection and immediately placed on
sponge membranes for short term culturing. Bronchi tissue
infected with the pandemic IFV A(H1N1) A/California/04/
2009 replicated the virus to high titer as analyzed at 24 and 48 hrs
post-infection. Bronchi tissue pretreated with DAS181 (2 hours at
10 mg/cm
2) revealed dramatically less viral replication at both
time points, as determined by TCID50 analysis of infectious viral
yield, with total inhibition at 48 hrs. Analysis of total viral yield in
tissue homogenates, by qRT-PCR analysis of viral M-gene RNA
level, corroborated the pandemic IFV A(H1N1) inhibition in
bronchi by DAS181 (Figure 3).
DAS181 Inhibits Pandemic Influenza A(H1N1) Clinical
Isolates in Mice
To better understand the affect of DAS181 on pandemic IFV
A(H1N1) infection in a mammalian animal model, the A/Mexico/
4108/2009 virus used to infect BALB/c mice in a manner yielding
significant lethality, body weight loss, and viral replication in the
lungs. Intranasal DAS181 treatment was performed daily for 5
days beginning 6 hours post-infection at several dose levels (0.3,
0.6, or 1 mg/kg/day). DAS181 treatment completely protected
against pandemic IFV A(H1N1)-induced lethality (Figure 4) and
reduced pandemic IFV A(H1N1)-induced body weight loss,
particularly at later time points in infection (.day 2) (Figure 5).
DAS181 treatment also reduced pandemic influenza A(H1N1)
viral replication in a dose-dependent manner, as measured by viral
titer in the lungs of the mice at day 3 and day 6 post-infection
(Figure 6). These results indicate that DAS181 effectively inhibits
novel pandemic influenza A(H1N1) virus replication and morbid-
ity in mice.
Discussion
The current outbreak of pandemic influenza A(H1N1) that was
first detected in Mexico is a reminder that IFV is an evolving
pathogen capable of significant reassortment events resulting in the
generation of novel strains. The ‘‘Spanish flu’’ pandemic of 1918–
1919 infected approximately 20% of the world’s population and
killed 20–50 million people, making it the most devastating disease
in all recorded history [31,32]. The initial epidemiology of the
pandemic influenza A(H1N1) virus suggests a lower case fatality
Table 1. DAS181 inhibits pandemic IFV A(H1N1): Number of Viral Foci in MDCK culture (per well).
Virus PBS DAS181 0.04 mM DAS181 0.16 mM DAS181 0.63 mM DAS181 2.5 mM DAS181 10 mM
A/Mexico/4604/2009 80691 60 0000
A/California/04/2009 180615 3611 60 000
A/Hawaii/31/2007 20665 612 61 000
A/Hawaii/21/2007 (H274Y) 2664 00000
MDCK cells were pretreated with DAS181 for 2 hours (at indicated concentrations) before infection with A/Mexico/4604/2009, A/California/04/2009, or seasonal
influenzas A/Hawaii/31/2007 or A/Hawaii/21/2007 (oseltamivir-resistant H274Y mutant) at M.O.I. ranging from 0.001 to 0.005 MOI. At 24 hrs p.i. the cells were
immunostained to detect NP viral antigen and the number of positive foci per individual well was counted (‘‘Number of Viral Foci’’). Simultaneously the viral yield in the
culture supernatants (media above the cell monolayers) collected from individual well was determined (Table 2). Values represent mean6SD of quadruplicate
experiments.
doi:10.1371/journal.pone.0007788.t001
Table 2. DAS181 inhibits pandemic IFV A(H1N1): Viral Yield in MDCK culture (log10 infectious particles per 100 ml).
Virus PBS DAS181 0.04 mM DAS181 0.16 mM DAS181 0.63 mM DAS181 2.5 mM DAS181 10 mM
A/Mexico/4604/2009 5.460.4 4.460.4 ,1 ,1 ,1 ,1
A/California/04/2009 3.5602 3.160.3 2.860.7 2.060.7 ,1 ,1
A/Hawaii/31/2007 5.460.4 3.261.1 2.561.2 ,1 ,1 ,1
A/Hawaii/21/2007 (H274Y) 5.360.3 ,1 2.362.4 ,1 ,1 ,1
MDCK cells were pretreated with DAS181 for 2 hours (at indicated concentrations) before infection with A/Mexico/4604/2009, A/California/04/2009, or seasonal
influenzas A/Hawaii/31/2007 or A/Hawaii/21/2007 (oseltamivir-resistant H274Y mutant) at M.O.I. ranging from 0.001 to 0.005 MOI. At 24 hrs p.i. the cells were
immunostained to detect NP viral antigen (Table 1). Simultaneously the viral yield in the culture supernatants (media above the cell monolayers) collected from
individual well was determined and expressed as log10 infectious particles per well (‘‘Viral Yield’’), a measure of released infectious viral progeny. Limit of detection in
viral yield assay is 10 infectious particles per 100 ml and all values below this are marked as ,1. Values represent mean6SD of quadruplicate experiments.
doi:10.1371/journal.pone.0007788.t002
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with regard to the potential for secondary waves of infection, as
occurred with the ‘‘Spanish flu’’, resulting in higher mortality
compared with the initial wave of infection [5].
Amidst a ,99% frequency of oseltamivir resistance in 2008–2009
seasonal A/H1N1 influenza isolates the novel 2009 pandemic
influenza A(H1N1) was fortuitously found to retain oseltamivir
sensitivity. However, this virus acquired the adamantane resistance-
conferring gene via a reassortment event [16,33,34]. Co-circulation of
viruses with different drug resistance profiles in humans poses a threat
of emergence of viruses resistant to both oseltamivir and adamantanes
[35]. Simultaneous infection of a single host with both strains could
lead to gene reassortment and ultimate production of a virus with both
oseltamivir-resistance and the characteristics of the novel influenza
A(H1N1) virus. The process of swapping gene segments between two
viral strains (segment reassortment, genetic drift) and has been widely
reported to be a major mechanism of viral evolution [36,37]. Because
the pandemic influenza A(H1N1) virus, or any other emerging strain
of influenza, could potentially gain the oseltamivir-resistance mutation
(H274Y) it is critical to continue to develop anti-influenza compounds
with alternative mechanisms of action.
DAS181 is a sialidase fusion protein currently in development
for use as a broad-spectrum inhibitor of influenza virus and
parainfluenza virus infection. DAS181 acts by reducing viral
binding to the respiratory epithelium, a novel mechanism of action
for anti-influenza drugs, and as such it complements existing anti-
influenza approaches. Furthermore, since DAS181 targets the host
cell, the potential for generating viral resistance may be less than
with traditional influenza inhibitors, which target the virus itself
(M2 inhibitors, neuraminidase inhibitors). Here we demonstrate
for the first time that DAS181 inhibits replication of several
pandemic influenza A(H1N1) viruses in MDCK cells, HAE
culture, ex vivo human bronchi tissue and in a murine model. The
effective inhibitory DAS181 concentration for the pandemic
influenza A(H1N1) viruses was similar to that with seasonal IFV,
suggesting that the pandemic influenza A(H1N1) viruses binds to
sialic acid residues comparably recognized by DAS181. This
finding highlights the potential broad spectrum activity of DAS181
against current and future IFV strains.
A common hallmark of novel IFV strains is altered sialic acid
(Sia) recognition. All influenza A viruses bind to terminal Sia acid
residues expressed on the cellular receptors. However, the
efficiency of this interaction depends on several factors such as
the structure of adjacent oligosaccharides. When avian or swine
viruses cross the inter-species barrier and infect humans they may
interact differently with the ‘human’ Sia-containing receptors, as
evidenced by HPAI H5N1 and 1918 ‘‘Spanish flu’’ viruses isolated
from clinical material [18,38,39]. While the exact Sia residues
recognized by these emerging strains (pandemic influenza
A(H1N1) or HPAI) may vary, DAS181 exhibits broad spectrum
sialic acid removal and therefore may be effective against current
and future influenza viruses with altered HA-Sia binding
specificity.
The data obtained using MDCK cell culture should be
interpreted with caution because this commonly used cell line
may not accurately represent the human respiratory tract in terms
Figure 2. DAS181 inhibits pandemic IFV A(H1N1): viral yield in
2009 A(H1N1) infected HAE culture. Well differentiated primary
human airway epithelium cultures (HAE) were pretreated with DAS181
for 2 hours (at 10 mM) before infection with either A/Mexico/4604/2009
or A/California/04/2009 at indicated infection levels. After 24 hrs the
apical wash was collected and viral yield was determined on MDCK cells
as described in Materials and Methods. Values represent mean6SD of
quadruplicate analysis of each sample.
doi:10.1371/journal.pone.0007788.g002
Figure 3. DAS181 inhibits pandemic IFV A(H1N1) viral
replication in ex vivo human bronchi tissue. Human bronchi
tissues were collected from patients undergoing lung resection and
immediately placed on air-liquid interface membranes for culturing.
Within 12 hours the tissues were pretreated with PBS (‘‘control’’) or
DAS181 (10 mg/cm
2, ‘‘2 h DAS181 pretreatment’’) for 2 hours at 37uC.
After washing, the tissues were infected with pandemic influenza
A(H1N1) A/California/04/2009 (10
6 TCID50/tissue) for 1 hr and then
washed. Tissues were then incubated at 37uC for 24 or 48 hrs before
washing the apical surface and determining viral titer in either the
apical wash by TCID50 on MDCK cells (top panel), or within tissue
homogenate by RT-PCR analysis of viral M-gene RNA level normalized
to cellular b-actin RNA level (bottom panel). Dotted line represents limit
of detection of the TCID50 assay.
doi:10.1371/journal.pone.0007788.g003
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Furthermore, the mouse infection data is limited by the fact that
the mouse and human respiratory systems present different viral
binding patterns [40,41], and the novel 2009 A(H1N1) virus is not
a mouse-adapted strain. As such the dynamics of 2009 A(H1N1)
infection shown in these models may not accurately represent
infection in humans. It should be noted that in the absence of daily
ketamine anesthesia, A/Mexico/4108/2009 does not result in
substantial morbidity or mortality in the mouse model. However,
the significant protective efficacy of DAS181 under these
experimental conditions is remarkable and the further evaluation
of DAS181 utilizing additional A(H1N1) viruses is warranted. In
contrast, the DAS181 effectiveness shown here in HAE culture
and ex vivo bronchi model, two of the most representative models of
the human respiratory tract, correlates with the MDCK and
mouse data and suggests that DAS181 may indeed be effective
against pandemic influenza A(H1N1) infections although further
clinical confirmation is required. Additionally, it will be valuable to
evaluate the affect of treatment timing relative to infection; in the
studies herein treatment was initiated within 6 hours of infection.
We have previously observed that NAIs, oseltamivir and
zanamivir, do not inhibit DAS181 activity in vitro or in vivo
(unpublished data). In cell culture, DAS181 exhibits a strongly
synergistic relationship with the NAIs against a panel of laboratory
IFV strains (unpublished data), although this has not been
examined in the context of 2009 A(H1N1) infection.
Because of the potential for emerging IFV strains to attain
oseltamivir resistance via reassortment with the current seasonal
H1N1 strain we also tested DAS181 activity against an
oseltamivir-resistant IFV. The most common mutation conferring
oseltamivir-resistance involves H274Y (H275Y in N1 numbering)
substitution in the neuraminidase of viruses of N1 antigenic
subtype (H1N1 and H5N1). This mutation was originally
identified in isolates from oseltamivir-treated individuals infected
with H1N1 virus [42], and more recently, in patients infected with
HPAI of H5N1 background, a troubling observation given the
pandemic potential and extremely virulent nature of this IFV
strain [43–45]. Perhaps more alarming was the finding that
seasonal H1N1 viruses, carrying the oseltamivir resistance-
conferring H274 mutation, emerged simultaneously in several
countries in 2007–2008, including countries where oseltamivir is
not prescribed [10,12–14]. The frequency of IFV isolates with this
mutation reached ,99.5% in the US in 2008–2009 [34]. Here we
show that influenza A/Hawaii/21/2007, one of the first
oseltamivir-resistant viruses from the 2007–2008 season, is highly
sensitive to DAS181 in MDCK cells. This in vitro finding indicates
that DAS181 may be active against currently circulating
oseltamivir-resistant IFV and further suggests that if novel strains,
such as the pandemic influenza A(H1N1) viruses, attain the
H274Y mutation, DAS181 may be active against these new
isolates as well. Additional testing of DAS181 sensitivity of several
NAI-resistant viruses is ongoing.
While the 2009 pandemic IFV A(H1N1) and the oseltamivir-
resistant seasonal IFV of 2007–2009 currently exhibit low case
Figure 4. DAS181 inhibits pandemic IFV A(H1N1)-induced
lethality in mice. BALB/c mice were inoculated with the pandemic
influenza A(H1N1) virus A/Mexico/4108/2009 (1000 MID50/mouse, i.n.).
The mice were treated with PBS or DAS181 (0.3, 0.6, or 1 mg/kg) q.d.x5,
beginning 6 hours post-infection. Survival was tracked daily for 14 days.
Values represent percent survival amongst 10 mice per group. All
DAS181 treated groups had 100% survival. Statistical significance from
PBS determined by Kaplan-Meier Log Rank Test, *=p,.05.
doi:10.1371/journal.pone.0007788.g004
Figure 5. DAS181 inhibits pandemic IFV A(H1N1)-induced
body weight loss in mice. BALB/c mice were inoculated with the
pandemic influenza A(H1N1) virus A/Mexico/4108/2009 (1000 MID50/
mouse, i.n.). The mice were treated with PBS or DAS181 (0.3, 0.6, or
1 mg/kg) q.d.x5, beginning 6 hours post-infection. Body weight was
measured daily for 14 days p.i., and is expressed normalized to starting
body weight. The data is collected from the same animals/study shown
in Figure 4. Values represent mean6SEM body weight change amongst
10 mice per group. Statistical significance from PBS determined by
analysis of Area Under Curve (AUC) with ANOVA and Bonferroni post-
test, *=p,0.05, ***=P,0.001.
doi:10.1371/journal.pone.0007788.g005
Figure 6. DAS181 inhibits pandemic IFV A(H1N1) viral
replication in mice. BALB/c mice were inoculated with the pandemic
influenza A(H1N1) virus A/Mexico/4108/2009 (1000 MID50/mouse, i.n.).
The mice were treated with PBS or DAS181 (0.3, 0.6, or 1 mg/kg) q.d.x5,
beginning 6 hours post-infection. Lungs were harvested on day 3 and
day 6 p.i.. Viral titer in lung homogenate was determined by standard
plaque assay on MDCK cells. Values represent mean6SEM viral titer
amongst 3 mice per group/day. PFU=plaque forming units. No virus
was detectable on day 6 in the DAS181 1.0 mg/kg treatment group.
Statistical significance from PBS treatment determined by ANOVA with
Bonferroni post-test, *=p,0.05, **=p,0.01, ***=p,0.001. The limit of
detection is 100 PFU/ml.
doi:10.1371/journal.pone.0007788.g006
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IFV’ propensity for rapid evolution, the constant threat of an
emerging highly virulent drug-resistant strain is concerning and
supports the need to monitor evolution of the 2009 A(H1N1) IFV
strains and simultaneously develop specific vaccines and novel
antivirals.
The safety and efficacy of DAS181 as a novel anti-IFV agent is
currently being evaluated in clinical trials. Based on its broad
spectrum preclinical in vitro and in vivo activity against seasonal and
potentially pandemic IFV, as well as against the 2009 pandemic
IFV A(H1N1) and oseltamivir-resistant IFV, DAS181 represents a
potentially valuable treatment option for emerging and drug-
resistant IFV.
Materials and Methods
Cells and Viruses
Madin Darby Canine Kidney (MDCK) cells were obtained
from American Type Culture Collection (Manassas, VA). Growth
and differentiation of primary human bronchial epithelial cells to
produce HAE culture were performed as described previously
[46,47]. Briefly, primary human bronchial cells (Cell Applications,
San Diego, CA) expanded to passage 3 were seeded in porous
membrane inserts (4.5 mm pore size, 12 mm diameter, Corning,
Corning, NY) at the density of 5610
4 cells/cm
2. Three days after
seeding the cells, the medium from the apical side was removed
and the confluent monolayers were cultured at an air-liquid
interface. The medium from the basal compartment was replaced
daily, and the in vitro differentiation of primary cells was achieved
after 4–6 weeks.
The seasonal A/Hawaii/31/2007 (H1N1) and closely related
A/Hawaii/21/2007 (H274Y) (H1N1) virus isolates, and the 2009
pandemic A(H1N1) virus isolates A/California/04/2009, A/
Mexico/4604/2009, and A/Mexico/4108/2009 were obtained
from Dr. Alexander Klimov, Influenza Division, Centers for
Disease Control and Prevention, Atlanta, Georgia, USA. The A/
California/04/2009, A/Mexico/4604/2009 viruses were propa-
gated in MDCK cells. The A/Mexico/4108/09 virus was isolated
from nasopharyngeal swabs collected from a patient with severe
respiratory illness and subsequently propagated in embryonated
hen’s eggs as previously described [22].
Determination of Virus Titer/Yield in Cell Culture
Supernatant by Immunofluorescence
Confluent MDCK cell monolayers in 96-well plates were
washed with PBS and infected with 10-fold virus dilutions (culture
media from treated/infected MDCKs or apical washes from
treated/infected HAE, see below). After 1 hour adsorption at 4uC,
unbound virus was removed and cells were overlaid by fresh
DMEM containing 0.2% BSA and 2 mg/ml TPCK-treated
trypsin. Plates were incubated at 37uC for 24 hours, at which
point, the supernatants were discarded and cells were fixed with
ice cold methanol/acetic acid (v/v 95/5). Fixed cell monolayers
were immunostained with primary anti-influenza A nucleoprotein
(NP) mouse monoclonal antibody (kind gift of Dr. Robert Webster,
St. Jude Children’s Research Hospital, Memphis, TN) and FITC-
conjugated secondary antibody (Sigma, St. Louis, MO). Cell
clusters (foci) expressing viral antigen NP were counted using a
fluorescent microscope (Axiovert 200, Zeiss, Germany) and viral
titers were calculated. An individual focus is formed by a cluster of
at least 5 neighboring virus infected cells, although a much greater
number of individual cells (,100) was observed in untreated
infected cells.
Testing DAS181 Sensitivity Using MDCK Infection
Confluent MDCK cells in 96-well plate format were pretreated
with DAS181 for 2 hours at 37uC (diluted in EDB-BSA buffer,
50 uL/well) before washing twice with PBS. MDCK cells were
then infected with the influenza strains at multiplicity (MOI)
ranging from 0.001 to 0.005. After 1 hr adsorption at 4uC, cells
were washed twice with PBS and replenished with fresh DMEM
media (containing 0.2% BSA and 2 mg/ml TPCK-treated trypsin).
Cultures were incubated at 37uC for 24 hrs at which point the
antiviral activity of DAS181 was determined in each well by two
criteria: a number of infectious centers (immunofluorescent foci)
(photo Fig. 1, Table 1) and viral yield in cell media (Table 1). Virus
yield in supernatants was determined as described above. Each
drug dilution was tested in quadruplicate and viral yield vales are
expressed as mean6standard deviation. The MDCK experiments
were performed twice, yielding comparable results.
Testing DAS181 Activity Using HAE Infection
HAE cultures in 12-well plate format were pretreated with
DAS181 for 2 hours at 37uC (diluted in EDB-BSA buffer,
100 uL/well) before washing with PBS and infection with the
novel 2009 A(H1N1) viruses. The cultures were infected with
1000, 100, or 10 infectious units per insert for 1 hr at 4uC before
washing with PBS. Cultures were incubated at 37uC for 24 hrs
before washing the apical surface of the culture with 200 ul PBS
and storing the collected wash at 280uC for quantitative
determination of viral titer as described above. The HAE
experiment was performed once.
Ex Vivo Human Bronchi Tissue Infection and Treatment
Fresh bronchi tissue was removed from patients undergoing
lung resection and immediately sectioned into multiple biopsies of
approximately 36565 mm dimensions. After sectioning, the
tissues were immediately placed on sponge membranes with
culture medium (F-12K nutrient mixture with L-glutamine, and
antibiotics) contacting the basal portion of the tissues (establish air-
liquid interface), before infection and/or DAS181 treatment
within 12 hours of resection. The tissues were treated with PBS
or DAS181 (10 ug/cm
2) for 2 hours at 37uC on the apical surface
before washing with PBS and then infecting with A/California/
04/09 for 1 hr at 37uC as described previously [48]. After washing
off unbound virus the tissues were incubated at 37uC for 24 or
48 hrs. At each time point the apical surface of the tissues was
washed with PBS and the viral titer in the apical wash was
determined by TCID50 analyses on MDCK cells. The ex vivo
bronchi experiment was performed twice (individual tissues/
patients), yielding comparable results. Each experiment was
analyzed by TCID50 and qRT-PCR.
qRT-PCR Analysis of Viral M-Gene RNA Level
Analysis of total viral yield in bronchi tissue homogenate was
performed as described previously [49]. In brief, total nucleic acid
was extracted from the bronchi tissue using NucliSens easyMAG
extraction system (bioMerieux, Netherlands) according to manu-
facturer’s instructions. 12 ml of extracted nucleic acid was used to
prepare cDNA by Invitrogen Superscript III kit with random
primer as described previously [50]. 2 ml of cDNA was amplified
in LightCycler with a total volume of 20 ml reaction containing
FastStart DNA Master SYBR Green I Mix reagent kit (Roche
Diagnostics GmbH, Germany), 4.0 mM MgCl2 and 0.5 mM of
each primer. The forward primer (59-CTTCTAACCGAGGTC-
GAAACG-39) and the reverse primer (59-GGCATTTTGGA-
CAAAKCGTCTA-3) were used for amplification corresponding
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expressed normalized to B-actin level. Cycling conditions were as
follows: an initial denaturation at 95uC for 10 minutes, followed by
40 cycles of 95uC for 10 seconds, 60uC for 3 seconds, 72uC for 12
seconds with ramp rates of 20uC/second. A series of dilutions were
prepared to generate calibration curves and run in parallel with
the test samples. At the end of the assay, PCR products were
subjected to a melting curve analysis to determine the specificity of
the assay.
Mouse Infection and Treatment
In a pilot experiment (not shown) the mouse 50% infectious
dose (MID50) was determined for the pandemic IFV A/Mexico/
4108/09 (,32 PFU/mouse). Female BALB/c mice, 10 to 11
weeks old, (The Jackson Laboratory, Bar Harbor, MI) were
randomly divided into 4 groups (16 mice/group). On day 0 all
mice were intranasally inoculated with 50 mL of A/Mexico/4108/
09 (1000 MID50/mouse=,32,000 PFU/mouse). All animals
were anesthetized via ketamine (100 mg/kg) and held in an
upright position when receiving the nasal drops. At 6 hours post-
inoculation all animals received the intranasal treatment of either
DAS181 or vehicle control (PBS) in 50 mL volume. Group 1
served as control and received PBS, and groups 2–4 received
DAS181 at 0.3, 0.6, or 1 ml/kg, respectively. Treatments were
repeated daily for a total of 5 treatments (q.d.x5). Ten mice per
group were observed daily for morbidity, as measured by weight
loss, or mortality, for 14 days post-infection (p.i.) Body weight is
represented as percent change from day 0 body weight
(immediately prior to experiment). For viral titer analysis, whole
lungs were collected from euthanized animals on day 3 and day 6
p.i. (3 mice/group/day). Lung tissues were collected and titrated
for virus as described previously [52]. The mouse experiment was
performed twice with comparable results. All animal research was
conducted under the guidance of CDC’s Institutional Animal care
and Use Committee and in an Association for Assessment and
Accreditation of Laboratory Animal Care International- accred-
ited facility.
Viral Titer Determination by Plaque Assay
Viral replication in mouse lung homogenate was quantified on
MDCK cells to determine infectious titer (plaque forming units per
mL, pfu/ml). In brief 6610-fold serial dilution was performed on
the lung homogenate samples followed by 1 hr binding at 37uCo n
confluent MDCK cells in 6-well plate format. After washing off
unbound virus with PBS, the cells were overlaid with 1:1 Noble
Agar (1.8%) and 2x DME-F12 (supplemented with Glutamax
(Invitrogen, Carlsbad, CA), ITS (Invitrogen), and 3 mg/ml
acetylated trypsin (Sigma, St. Louis, MO)). After allowing agar
to solidify, the plates were incubated for ,48 hrs at 37uC before
fixing with ethanol and staining with crystal violet and counting
plaque number at each dilution.
Data Analysis
All data was graphed with Prism 4.02 software and significance
was determined by ANOVA with Bonferroni post-test, except for
mouse survival studies which utilized Kaplan-Meier Log Rank
test.
Acknowledgments
We thank Alexander Klimov for generously providing viruses and for
valuable discussion of the data. We thank Mang Yu for critical evaluation
of this manuscript.
Author Contributions
Conceived and designed the experiments: GBTB LG JMN VPM JAB MH
JLL RBm TMT FF. Performed the experiments: LG JMN MBP VPM JAB
LMC RWYC MCC. Analyzed the data: GBTB LG JMN VPM LMC
RWYC MH RBm JMK TMT FF. Contributed reagents/materials/
analysis tools: GBTB LG JMN VPM RWYC JMK TMT FF. Wrote the
paper: GBTB JLL.
References
1. Cox NJ, Subbarao K (2000) Global epidemiology of influenza: past and present.
Annu Rev Med 51: 407–421.
2. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, et al. (2003)
Mortality associated with influenza and respiratory syncytial virus in the United
States. JAMA 289: 179–186.
3. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team (2009)
Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in Humans.
N Engl J Med.
4. Belshe RB (2009) Implications of the Emergence of a Novel H1 Influenza Virus.
N Engl J Med.
5. Miller MA, Viboud C, Balinska M, Simonsen L (2009) The Signature Features
of Influenza Pandemics–Implications for Policy. N Engl J Med.
6. Shinde V, Bridges CB, Uyeki TM, Shu B, Balish A, et al. (2009) Triple-
Reassortant Swine Influenza A (H1) in Humans in the United States, 2005–
2009. N Engl J Med.
7. CDC (2009) Serum Cross-Reactive Antibody Response to a Novel Influenza A
(H1N1) Virus After Vaccination with Seasonal Influenza Vaccine. Morbidity
Mortality Weekly Report 58: 521–524.
8. Hatakeyama S, Sugaya N, Ito M, Yamazaki M, Ichikawa M, et al. (2007)
Emergence of influenza B viruses with reduced sensitivity to neuraminidase
inhibitors. JAMA 297: 1435–1442.
9. Hayden FG, Hay AJ (1992) Emergence and transmission of influenza A viruses
resistant to amantadine and rimantadine. Curr Top Microbiol Immunol 176:
119–130.
10. Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, et al. (2008)
Surveillance for neuraminidase inhibitor resistance among human influenza A
and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents
Chemother 52: 3284–3292.
11. Suzuki H, Saito R, Masuda H, Oshitani H, Sato M, et al. (2003) Emergence of
amantadine-resistant influenza A viruses: epidemiological study. J Infect Che-
mother 9: 195–200.
12. Dharan NJ, Gubareva LV, Meyer JJ, Okomo-Adhiambo M, McClinton RC, et
al. (2009) Infections with oseltamivir-resistant influenza A(H1N1) virus in the
United States. JAMA 301: 1034–1041.
13. Moscona A (2005) Oseltamivir resistance–disabling our influenza defenses.
N Engl J Med 353: 2633–2636.
14. Moscona A (2009) Global transmission of oseltamivir-resistant influenza.
N Engl J Med 360: 953–956.
15. Hayden F (2009) Developing new antiviral agents for influenza treatment: what
does the future hold? Clin Infect Dis 48 Suppl 1: S3–13.
16. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, et al. (2009) Antigenic
and Genetic Characteristics of Swine-Origin 2009 A(H1N1) Influenza Viruses
Circulating in Humans. Science.
17. Shinya K, Ebina M, Yamada S, Ono M, Kasai N, et al. (2006) Avian flu:
influenza virus receptors in the human airway. Nature 440: 435–436.
18. Stevens J, Blixt O, Tumpey TM, Taubenberger JK, Paulson JC, et al. (2006)
Structure and receptor specificity of the hemagglutinin from an H5N1 influenza
virus. Science 312: 404–410.
19. Malakhov MP, Aschenbrenner LM, Smee DF, Wandersee MK, Sidwell RW, et
al. (2006) Sialidase fusion protein as a novel broad-spectrum inhibitor of
influenza virus infection. Antimicrob Agents Chemother 50: 1470–1479.
20. Nicholls JM, Aschenbrenner LM, Paulson JC, Campbell ER, Malakhov MP, et
al. (2008) Comment on: concerns of using sialidase fusion protein as an
experimental drug to combat seasonal and pandemic influenza. J Antimicrob
Chemother 62: 426–428.
21. Ito T (2000) Interspecies transmission and receptor recognition of influenza A
viruses. Microbiol Immunol 44: 423–430.
22. Belser JA, Lu X, Szretter KJ, Jin X, Aschenbrenner LM, et al. (2007) DAS181, a
novel sialidase fusion protein, protects mice from lethal avian influenza H5N1
virus infection. J Infect Dis 196: 1493–1499.
23. Nicholls JM, Chan RWY, Chan MCW, Peiris M, Fang F (2009) DAS181
(Fludase(r)) Inhibits H5N1 Influenza virus Infection of Human Lung Tissues.
Manuscript in review. Antimicrob Agents Chemother.
24. Triana-Baltzer GB, Nicholls JM, Chan RWY, Peiris JS, Chan MCW, et al.
(2009) DAS181, A Sialidase Fusion Protein, Protects Human Airway Epithelium
against Influenza Virus Infection: An In Vitro Pharmacodynamic Analysis.
Manuscript in Preparation.
DAS181 Inhibits Pandemic H1N1
PLoS ONE | www.plosone.org 7 November 2009 | Volume 4 | Issue 11 | e778825. Gray TE, Guzman K, Davis CW, Abdullah LH, Nettesheim P (1996)
Mucociliary differentiation of serially passaged normal human tracheobronchial
epithelial cells. Am J Respir Cell Mol Biol 14: 104–112.
26. Hatakeyama S, Sakai-Tagawa Y, Kiso M, Goto H, Kawakami C, et al. (2005)
Enhanced expression of an alpha2,6-linked sialic acid on MDCK cells improves
isolation of human influenza viruses and evaluation of their sensitivity to a
neuraminidase inhibitor. J Clin Microbiol 43: 4139–4146.
27. Matrosovich M, Matrosovich T, Carr J, Roberts NA, Klenk HD (2003)
Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases
influenza virus sensitivity to neuraminidase inhibitors 1. J Virol 77: 8418–8425.
28. Nettesheim P, Koo JS, Gray T (2000) Regulation of differentiation of the
tracheobronchial epithelium. J Aerosol Med 13: 207–218.
29. Thompson CI, Barclay WS, Zambon MC, Pickles RJ (2006) Infection of human
airway epithelium by human and avian strains of influenza a virus. J Virol 80:
8060–8068.
30. Thornton DJ, Gray T, Nettesheim P, Howard M, Koo JS, et al. (2000)
Characterization of mucins from cultured normal human tracheobronchial
epithelial cells. Am J Physiol Lung Cell Mol Physiol 278: L1118–L1128.
31. Johnson NP, Mueller J (2002) Updating the accounts: global mortality of the
1918–1920 ‘‘Spanish’’ influenza pandemic. Bull Hist Med 76: 105–115.
32. Taubenberger JK, Morens DM (2006) 1918 Influenza: the mother of all
pandemics. Emerg Infect Dis 12: 15–22.
33. CDC (2009) Update: drug susceptibility of swine-origin influenza A (H1N1)
viruses, April 2009. MMWR Morb Mortal Wkly Rep 58: 433–435.
34. CDC (2009) ‘‘Flu View’’ Weekly U.S. Influenza Surveillance Report for Week 15
ending April 18 2009. http://www.cdc.gov/flu/weekly/weeklyarchives2008-2009/
weekly15.htm.
35. Cheng P, Leung T, Ho E, Leung P, Ng A, et al. (2009) Oseltamivir- and
Adamantine-resistant influenza viruses A (H1N1). Emerg Infect Dis 15:
966–968.
36. Nelson MI, Viboud C, Simonsen L, Bennett RT, Griesemer SB, et al. (2008)
Multiple reassortment events in the evolutionary history of H1N1 influenza A
virus since 1918. PLoS Pathog 4: e1000012.
37. Simonsen L, Viboud C, Grenfell BT, Dushoff J, Jennings L, et al. (2007) The
genesis and spread of reassortment human influenza A/H3N2 viruses conferring
adamantane resistance. Mol Biol Evol 24: 1811–1820.
38. Stevens J, Blixt O, Glaser L, Taubenberger JK, Palese P, et al. (2006) Glycan
microarray analysis of the hemagglutinins from modern and pandemic influenza
viruses reveals different receptor specificities. J Mol Biol 355: 1143–1155.
39. Stevens J, Blixt O, Chen LM, Donis RO, Paulson JC, et al. (2008) Recent avian
H5N1 viruses exhibit increased propensity for acquiring human receptor
specificity. J Mol Biol 381: 1382–1394.
40. Ibricevic A, Pekosz A, Walter MJ, Newby C, Battaile JT, et al. (2006) Influenza
virus receptor specificity and cell tropism in mouse and human airway epithelial
cells. J Virol 80: 7469–7480.
41. van Riel D, Munster VJ, de Wit E, Rimmelzwaan GF, Fouchier RA, et al. (2006)
H5N1 Virus Attachment to Lower Respiratory Tract. Science 312: 399.
42. Gubareva LV, Kaiser L, Matrosovich MN, Soo-Hoo Y, Hayden FG (2001)
Selection of influenza virus mutants in experimentally infected volunteers treated
with oseltamivir. J Infect Dis 183: 523–531.
43. Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, Hayden FG, Nguyen DH, et
al. (2008) Update on avian influenza A (H5N1) virus infection in humans.
N Engl J Med 358: 261–273.
44. de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, et al. (2005)
Oseltamivir resistance during treatment of influenza A (H5N1) infection.
N Engl J Med 353: 2667–2672.
45. Gupta RK, Nguyen-Van-Tam JS (2006) Oseltamivir resistance in influenza A
(H5N1) infection. N Engl J Med 354: 1423–1424.
46. Chen LM, Davis CT, Zhou H, Cox NJ, Donis RO (2008) Genetic compatibility
and virulence of reassortants derived from contemporary avian H5N1 and
human H3N2 influenza A viruses. PLoS Pathog 4: e1000072.
47. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD (2004)
Human and avian influenza viruses target different cell types in cultures of
human airway epithelium. Proc Natl Acad Sci U S A 101: 4620–4624.
48. Nicholls JM, Chan MC, Chan WY, Wong HK, Cheung CY, et al. (2007)
Tropism of avian influenza A (H5N1) in the upper and lower respiratory tract.
Nat Med 13: 147–149.
49. Cowling BJ, Fung RO, Cheng CK, Fang VJ, Chan KH, et al. (2008)
Preliminary findings of a randomized trial of non-pharmaceutical interventions
to prevent influenza transmission in households. PLoS ONE 3: e2101.
50. Peiris JS, Tang WH, Chan KH, Khong PL, Guan Y, et al. (2003) Children with
respiratory disease associated with metapneumovirus in Hong Kong. Emerg
Infect Dis 9: 628–633.
51. Chan KH, Peiris JS, Lim W, Nicholls JM, Chiu SS (2008) Comparison of
nasopharyngeal flocked swabs and aspirates for rapid diagnosis of respiratory
viruses in children. J Clin Virol 42: 65–69.
52. Lu X, Tumpey TM, Morken T, Zaki SR, Cox NJ, et al. (1999) A mouse model
for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses
isolated from humans. J Virol 73: 5903–5911.
DAS181 Inhibits Pandemic H1N1
PLoS ONE | www.plosone.org 8 November 2009 | Volume 4 | Issue 11 | e7788